Federal Trade Commission accuses three drug middlemen of inflating insulin prices
In a lawsuit, the FTC accused Optum Rx, Caremark and Express Scripts of creating "a broken rebate system that inflated insulin drug prices, boosting PBM (prescription drug benefit managers) profits at the expense of vulnerable patients.
A Federal Trade Commission (FTC) report found that social and video streaming services pose serious privacy risks, especially ...
Commercially available location data has outed Planned Parenthood visitors and gay priests — and a newly published research ...
Three companies that process about 80% of prescriptions in the United States — Caremark, Express Scripts and OptumRx — have ...
Cigna Group’s Express Scripts sued the US Federal Trade Commission over a recent report that the company said demonizes ...
Headquartered in North St. Louis County, Express Scripts, a subsidiary of The Cigna Group, is demanding the FTC retract a ...
Last month, the Federal Trade Commission (FTC) and U.S. Department of Justice (DOJ) jointly hosted a public meeting of the interagency “Strike ...
The Federal Trade Commission took action Friday against the nation’s three largest pharmacy benefit managers, accusing the companies of artificially inflating insulin list prices that resulted ...
The investigation also highlights the companies' failure to adequately protect users, particularly children and teenagers.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback